← Back to Search

Enzyme Inhibitor

Salt-Sensitivity Blood Pressure Study in Healthy Subjects

N/A
Waitlist Available
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after 1 week dietary salt manipulation on both diets

Summary

This trial will study how salt affects blood pressure by looking at the salt-sensitive regulatory enzyme Lysine-specific demethylase 1.

Who is the study for?
This trial is for healthy Caucasian or African American individuals aged 25-45, with normal blood pressure and no history of major diseases like hypertension, diabetes, or heart disease. Participants must not be overweight (BMI <25), drink more than 6oz alcohol weekly, use tobacco/drugs/NSAIDs, be pregnant/breastfeeding, have certain drug sensitivities or recent steroid use.
What is being tested?
The study aims to understand how dietary salt affects blood pressure regulation through the enzyme Lysine-specific demethylase 1. It will measure changes in vascular stiffness, kidney blood flow response to salt intake and aldosterone levels after Angiotensin II infusion.
What are the potential side effects?
Potential side effects may include reactions to infused substances such as Angiotensin II which can cause changes in blood pressure or allergic responses. However, since this is a study on healthy subjects without underlying conditions and focuses on observation rather than treatment intervention, fewer side effects are expected.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after 1 week dietary salt manipulation
This trial's timeline: 3 weeks for screening, Varies for treatment, and after 1 week dietary salt manipulation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Aldosterone response to angiotensin II
Secondary study objectives
Renal blood flow response to dietary salt
Vascular stiffness response to angiotensin II

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Afr-Amer risk alleleActive Control3 Interventions
African Americans carrying the LSD1 affected allele
Group II: Cauc risk allelePlacebo Group3 Interventions
Caucasians carrying the LSD1 affected allele
Group III: Cauc non-risk allelePlacebo Group3 Interventions
Caucasians carrying the LSD1 non-risk allele
Group IV: Afr-Amer non-risk allelePlacebo Group3 Interventions
African Americans carrying the LSD1 non-risk allele

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,666 Previous Clinical Trials
11,840,147 Total Patients Enrolled

Media Library

Lysine-specific demethylase 1 inhibitor (Enzyme Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03029806 — N/A
Healthy Subjects Research Study Groups: Afr-Amer risk allele, Cauc risk allele, Cauc non-risk allele, Afr-Amer non-risk allele
Healthy Subjects Clinical Trial 2023: Lysine-specific demethylase 1 inhibitor Highlights & Side Effects. Trial Name: NCT03029806 — N/A
Lysine-specific demethylase 1 inhibitor (Enzyme Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03029806 — N/A
~10 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top